Alembic Pharma gets USFDA nod for seizure treatment drug
The approval from is for the company’s abbreviated new drug application (ANDA) for Clonazepam orally disintegrating tablets, in the strengths of 0.125 mg, 0.25 mg, 0.5 mg, 1 mg and 2 mg
Alembic Pharmaceuticals said it has received approval from the US health regulator for Clonazepam orally disintegrating tablets, used for treatment of seizures.
The approved product is therapeutically equivalent to the reference listed drug Klonopin orally disintegrating tablets of Hoffmann-La Roche, Inc.
The approval from the United States Food and Drug Administration (USFDA) is for the company’s abbreviated new drug application (ANDA) for Clonazepam orally disintegrating tablets, in the strengths of 0.125 mg, 0.25 mg, 0.5 mg, 1 mg and 2 mg, Alembic Pharmaceuticals said in a filing to BSE.
Quoting IQVIA data, Alembic Pharma said Clonazepam orally disintegrating tablets USP has an estimated market size of $20 million for 12 months ending December 2018.
Clonazepam orally disintegrating tablet is useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures.
The company currently has a total of 98 ANDA approvals (86 final approvals and 12 tentative approvals) from USFDA, it added.
- Advertisement -